Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects

NCT04030559 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT04030559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04030559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Terminated
Start date
February 25, 2020
Completion date
November 7, 2025
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atm gene mutation, brca1 gene mutation, brca2 gene mutation, brip1 gene mutation, cdk12 gene mutation, chek1 gene mutation, chek2 gene mutation, dna damage response gene mutation, dna repair gene mutation, fanca gene mutation, fancd2 gene mutation, fancl gene mutation, gen1 gene mutation, nbn gene mutation, prostate carcinoma, rad51 gene mutation, rad51c gene mutation